RMD

ResMed operates with a distinctive profitability profile in the medical device sector, posting a net margin of 27.44% alongside an ROE of 24.41%—metrics that systematic screening highlights as exceptional within capital-intensive healthcare equipment manufacturing. The company's current price of $204.15 sits 30.5% below its 52-week high of $293.81, creating a notable valuation compression despite sustained operational momentum reflected in 10.28% revenue growth and 16.47% EPS expansion year-over-year.

The fundamental screening model identifies several structural strengths:

• Balance sheet resilience: A debt-to-equity ratio of just 0.11 combined with a current ratio of 3.44 positions the company with substantial financial flexibility for continued R&D investment in sleep apnea and respiratory care technologies
• Operational efficiency: Operating margin of 34.18% demonstrates pricing power and manufacturing scale in connected device platforms
• Valuation context: Trading at 19.56x trailing earnings and 5.37x sales represents a moderate multiple relative to the $29.6B market capitalization

Risk factors include the substantial price correction from recent peaks and a beta of 0.83, suggesting ongoing market reassessment of growth durability. Book value per share of $40.77 yields a price-to-book of 6.34x, indicating premium expectations embedded in current valuation despite the pullback.

Relative to peers SYK, BSX, and EW, ResMed's 24.41% ROE stands among sector leaders while maintaining conservative leverage—a combination the quantitative model flags as indicative of sustainable competitive positioning in connected respiratory device markets.